Baystate Wealth Management’s AnaptysBio ANAB Stock Holding History

Baystate Wealth Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2	Closed	–	–	675
2020 Q3	$0	Buy	+2	New	+$36	﹤0.01%	635

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Baystate Wealth Management's ANAB Position: Q4 2020 in Review

Baystate Wealth Management sold out of AnaptysBio (ANAB) in Q4 2020, closing a stake of 2 shares.

Baystate Wealth Management first reported a position in ANAB in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 136 funds tracked by Wall St. Rank hold ANAB as of Q4 2020.

Baystate Wealth Management reported no remaining AnaptysBio position as of Q4 2020 after selling out during the quarter.
Baystate Wealth Management sold 2 AnaptysBio shares in Q4 2020.
Baystate Wealth Management first reported a position in AnaptysBio in Q3 2020 and held it in 1 quarter.
Baystate Wealth Management's AnaptysBio position peaked at $0 in Q3 2020.
136 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2020.

Based on Baystate Wealth Management's 13F filing for Q4 2020, filed 15 Jan 2021.